E89R
TEAS SECTION 8 & 9 RECEIVED
08/14/2026
Back to search
Official data from USPTO
BIOMODULINA T
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BIOMODULINA T
ST13
US500000086490752Class
5
Filing
86490752
Registration
5070926
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
08/14/2026
Trademark type
Word
Nice classes
5
Filing date
12/26/2014
Registration date
11/01/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/12/2023
Last transaction
08/14/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
First use anywhere
07/02/1993
First use in commerce
07/31/2012
Drawing code
4
Owner type
16
Owner location
MIAMI, FL, US
Examiner
GALAN, MATTHEW
Current location
FILE DESTROYED
Holders and representatives
Holders
BIOLONG, LLC.
Representatives
BIOLONG, LLC.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
PHARMACEUTICAL PREPARATIONS FOR PREVENTING AND TREATING DISORDERS OF THE IMMUNE SYSTEM; NUTRITIONAL SUPPLEMENTS
Publications
History of USPTO decisions and trademark events.
46 publications found
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
11/01/2025
NA15
SEC. 15 ACKNOWLEDGEMENT - E-MAILED
10/31/2024
15AK
REGISTERED - SEC. 15 ACKNOWLEDGED
10/31/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/31/2024
E15R
TEAS SECTION 15 RECEIVED
06/27/2024
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
04/12/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
04/12/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/12/2023
ES8R
TEAS SECTION 8 RECEIVED
09/01/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/01/2021
CORV
REVIEW OF CORRESPONDENCE COMPLETE - POWER OF ATTORNEY ENTERED
11/27/2018
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
11/27/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2016
PUBO
PUBLISHED FOR OPPOSITION
08/16/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/11/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
06/27/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/27/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
06/27/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/27/2016
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
06/22/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/07/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/07/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/06/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/30/2015
GNFR
FINAL REFUSAL E-MAILED
12/30/2015
CNFR
FINAL REFUSAL WRITTEN
12/30/2015
ACEC
AMENDMENT FROM APPLICANT ENTERED
12/29/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/29/2015
PAPER RECEIVED
12/22/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/27/2015
GNRT
NON-FINAL ACTION E-MAILED
10/27/2015
CNRT
NON-FINAL ACTION WRITTEN
10/27/2015
ACEC
AMENDMENT FROM APPLICANT ENTERED
10/06/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/06/2015
ALIE
ASSIGNED TO LIE
09/29/2015
PAPER RECEIVED
09/14/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/07/2015
GNRT
NON-FINAL ACTION E-MAILED
04/07/2015
CNRT
NON-FINAL ACTION WRITTEN
04/07/2015
DOCK
ASSIGNED TO EXAMINER
04/06/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2015
NWAP
NEW APPLICATION ENTERED
12/30/2014
Continuous trademark protection
Get notified about every new filing that threatens BIOMODULINA T or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.